Natco Pharma Ltd.

NATCOPHARM

Market Cap
₹17,719 Cr.
P/E
13.87

Natco Pharma Ltd.

Quick View
  • 1d
  • 1m
  • 6m
  • YTD
  • 1y
  • 3y
  • 5y
  • 10y
  • max
locked

Company Timeline

Company Timeline

Subscribe now for more updates
Forensics

9 Yes

Positive for this company

2 Neutral

Neutral for this company

6 No

Negative for this company

0 No Data

Insufficient data to analyse

ROE
Latest
14.68%
3yr Average
9.79%
5yr Average
12.01%
Net Profit Margin
Latest
26.42%
3yr Average
18.88%
5yr Average
22.3%
ROCE
Latest
17.62%
3yr Average
12.17%
5yr Average
15.05%
Debt to Equity
Latest
0.03
3yr Average
0.06
5yr Average
0.08
Market Share
0.07% (as of Jul 22)
Anti - Diabetes - Market Share
0.74% (as of Jul 22)
Anti-Infectives - Market Share
16.71% (as of Nov 21)
Antineo Plastic - Market Share
0.11% (as of Nov 21)
Blood Related - Market Share
0.56% (as of Jul 22)
Cardiovascular - Market Share
30% (as of Mar 19)
Copaxone - Market Share
locked Source
0% (as of Jul 22)
Gastro-Intestinal - Market Share
0.01% (as of Jul 21)
Neurological - Market Share
0.38% (as of Nov 21)
Pain - Market Share
0.47% (as of Jul 22)
Pharmaceutical Sector - Market Share
0.30% (as of May 21)
Respiratory - Market Share
34.62% (as of May 19)
Urology - Market Share
Show more
Revenue mix

Product Wise Break-Up

locked
Source
|
Latest
|
locked
Historic

Segment Break-Up

locked
Source
|
Latest
|
locked
Historic

Therapeutic Area Wise Break-Up - Domestic

locked
Source
|
Latest
|
locked
Historic

Location Wise Break-Up -Formulation

locked
Source
|
Latest
|
locked
Historic

Location Wise Break-Up

locked
Source
|
Latest
|
locked
Historic

Therapeutic Area Break-Up -Formulation

locked
Source
|
Latest
|
locked
Historic

Operating Profit Break-Up

locked
Source
|
Latest
|
locked
Historic

Asset Break-Up

locked
Source
|
Latest
|
locked
Historic
Show more
Operational Metrics

    locked
    Select a Metric
    • US DMF Filings (.)
      Source
    • Number of ANDA's Filed in USA (.)
      Source
    • Number of ANDA's Approved By USFDA (.)
      Source
    • Domestic Sales Growth - YoY (%)
      Source
    • R&D as a % of Total Sales (%)
      Source
    Peer Comparison
    Brands
    Afinitor
    Aubagio
    Imbruvica
    Kyprolis
    Nexavar
    Pomalyst
    Revlimid
    Sovaldi
    Tarceva
    Tykerb
    Zytiga
    Suppliers
    Company Filing
    Show Previous Years
    Discussions & Analysis
    Natco Pharma Ltd.
    Natco Pharma: Business Model Simplified - JST Investments
    Chasing Optionalities - SOIC
    View the discussion on ValuePickr
    Natco Pharma: Chasing Optionalities - Ankush Agrawal
    Interview with Mr Rajeev Nannapaneni, Vice Chairman & CEO at Natco Pharma - Moneylife
    Business Analysis Of Natco Pharma - Value Educator
    NatcoPharma - Complex generics focused manufacturer - Value Educator
    Natco Pharma: Imminent Growth Cycle (?) - ValuePickr
    A Deep Dive Into Natco Pharma - Numbers and Narratives
    Pharmaceutical Sector
    How The Pharma Industry Works - PPFAS
    Phama Industry - Terminologies and Value Chain - Alpha Invesco
    Deep Dive into Pharma Sector - Omkara Capital
    Pharma Compliance In-Depth - Amit Rajan
    Nutraceuticals - The Next Gem of Healthcare Sector - Shuchi Nahar
    Nutraceuticals- Industry Overview - Value Educator
    Generic Opportunity for Indian Pharma Companies - Anish Moonka
    timeline